The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
NCT06620809 is a phase 1 interventional trial sponsored by Tongji Hospital. As of 18 Nov 2026, it is recruiting participants. It studies A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection in Neuromyelitis Optica Spectrum Disorders. The registry lists an enrollment of 69 participants at 1 site in 1 country. The registry lists a start date of 28 Mar 2025 and a primary completion date of 30 Nov 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06620809 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Tongji Hospital |
| Enrollment | 69 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Neuromyelitis Optica Spectrum Disorders |
| Drugs | A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection |
| Start | 28 Mar 2025 |
| Primary completion | 30 Nov 2027 |
| Study completion | 30 Nov 2027 |
| Last update posted | 21 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Chuan Qin, MD
Tongji Hospital
Principal Investigator - Dai-shi Tian, MD
Tongji Hospoital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tongji Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei
Recruiting
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06620809
Each answer restates registry values shown on this page.
What is NCT06620809?
NCT06620809 is a phase 1 interventional trial sponsored by Tongji Hospital. It studies A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection in Neuromyelitis Optica Spectrum Disorders.
Is NCT06620809 recruiting?
As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT06620809?
The registry names Chuan Qin, MD (principal investigator, Tongji Hospital), Dai-shi Tian, MD (principal investigator, Tongji Hospoital) and Wei Wang, MD (principal investigator, Tongji Hospoital) as overall officials.
Where does NCT06620809 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.
Which drugs does NCT06620809 study?
The registered drug and biological interventions are A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection.
When is NCT06620809 expected to complete?
The registry lists a primary completion date of 30 Nov 2027 and a study completion date of 30 Nov 2027. The sponsor last updated the record on 21 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.